# Massachusetts General Hospital

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/massachusetts-general-hospital
Canonical HTML page: https://getbiobrief.com/entity/massachusetts-general-hospital

## Timeline

- **2026-Q4**: Interim Analysis — Expected window for preliminary safety and biomarker data review by the trial committee.
- **2026-02-26**: Dosing Initiation — First patient dosed with NUZ-001 in the multi-center Phase 2/3 study.
- **2024-12**: Trial Selection — NUZ-001 selected as a new regimen for the HEALEY ALS Platform Trial.

## Recent coverage (2 stories)

### Lung and stomach cancer waits jump 12–14 days, raising progression risk
2026-08-18 22:36:13 · Sentiment: Negative · Impact: 6/10 · Sources: 2

Diagnosis-to-treatment intervals grew for six early-stage cancers from 2012–2023, with lung (+12 days) and stomach (+14 days) leading. For biopharma, longer real-world waits threaten neoadjuvant therapy windows and perioperative trial design.
Full story: https://getbiobrief.com/story/cancer-wait-time-clinical-implications-biopharma

### Neurizon Begins Dosing NUZ-001 in Landmark HEALEY ALS Platform Trial
2026-02-26 22:41:08 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Neurizon has officially commenced patient dosing for NUZ-001 in the HEALEY ALS Platform Trial, a multi-center study led by Massachusetts General Hospital. This milestone marks a critical transition for the biotech as it seeks to validate its mTOR inhibitor as a disease-modifying therapy for Amyotrophic Lateral Sclerosis.
Full story: https://getbiobrief.com/story/neurizon-nuz-001-healey-als-trial-dosing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.